NARA Discovery
Article Details
← Back to Search Results
Journal Article

Biochemical study of the effect of mesenchymal stem cells-derived exosome versus l-Dopa in experimentally induced Parkinson’s disease in rats

Asmaa S. Mohamed; Dina S. Abdel-Fattah; Ghada A. Abdel-Aleem; Thanaa F. El-Sheikh; Manal M. Elbatch
Molecular and Cellular Biochemistry · Vol. 478, Issue 12 · pp. 2795-2811 · 2023

Abstract

Parkinson’s disease (PD) is a chronic and ongoing neurological condition. Unfortunately, as the dopaminergic terminals continue to deteriorate, the effectiveness of anti-Parkinson therapy decreases. This study aimed to examine the effects of BM-MSCs-derived exosomes in rats induced with Parkinson’s disease. The goal was to determine their potential for neurogenic repair and functional restoration. Forty male albino rats were divided into four groups: control (group I), PD (group II), PD- l -Dopa (group III), and PD-exosome (group IV). Motor tests, histopathological examinations, and immunohistochemistry for tyrosine hydroxylase were performed on brain tissue. The levels of α-synuclein, DJ-1, PARKIN, circRNA.2837, and microRNA-34b were measured in brain homogenates. Rotenone induced motor deficits and neuronal alterations. Groups (III) and (IV) showed improvement in motor function, histopathology, α-synuclein, PARKIN, and DJ-1 compared to group (II). Group (IV) showed improvement in microRNA-34b and circRNA.2837 compared to groups (III) and (II). MSC-derived exosomes showed a greater suppression of neurodegenerative disease (ND) compared to l -Dopa in Parkinson’s patients. Graphical abstract

Bibliographic Information

JournalMolecular and Cellular Biochemistry
PublisherSpringer
Publication Date2023-12-01
Publication Year2023
Volume478
Issue12
Pages2795-2811
Document TypeJournal Article
eISSN1573-4919
DOI10.1007/s11010-023-04700-8

Access Information

NARA Access Coverage1973-01-01~Current
Journal Homepagehttps://www.springer.com/journal/11010
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.